← Calendar
Readoutin 14d
Jiangsu HengRui Medicine Co., Ltd. — SHR0302 tablets、Placebo
Phase 3 primary completion: To Evaluate the Efficacy and Safety of SHR0302 Tablet in Subjects of Active Psoriatic Arthritis.
- Date
- Dec 2026
- Type
- Readout
- Indication
- Psoriatic Arthritis
Source ↗Add to calendar
Get told when this date moves
The weekly brief is free. Pro adds reminders 7 days and 1 day before.
More from Jiangsu HengRui Medicine Co., Ltd.
Dec2026
Readoutin 14d
Jiangsu HengRui Medicine Co., Ltd. — Fuzuloparib , Abiraterone acetate and PrednisonePhase 3 primary completion: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer.
Dec2026
Readoutin 14d
Jiangsu HengRui Medicine Co., Ltd. — SHR-A1811Phase 3 primary completion: A Trial of SHR-A1811versus Pyrotinib in Combination With Capecitabine in HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane.